Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Obducat receives order valued at 1.1 million SEK from an existing customer in Europe

OBDUCAT AB (publ) subsidiary Obducat Europe GmbH, a leading supplier of system solutions for lithography processing, has received a purchase order from an existing customer in Europe, for the supply of a QS resist processing tool. The order value amounts to approx. 1.1 million SEK. The customer is a leading manufacturer of Photonics components. The QS system is configured to perform photoresist coating processes in conjunction with the development of Photonics components. Further information cannot be disclosed for the time being due to confidentiality obligations. The QS tool will be

Coor awarded gold rating by EcoVadis

Coor has been awarded the gold rating in EcoVadis’ annual international rankings. EcoVadis is an independent analyst that provides annual sustainability ratings for companies.The gold rating from EcoVadis places Coor among the top 5% of global companies in terms of its CSR work. “We’re very proud to have achieved a gold rating in EcoVadis’ review and consider it recognition of our far-reaching commitment to sustainability,” commented AnnaCarin Grandin, President and CEO of Coor. The rating was awarded following an extensive review of Coor’s work. EcoVadis’ assessment is based on 21

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 27th September 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 25,869,081 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Autonomous vehicles to enhance safety at sawmills

With the help of Semcon, two of Sweden’s largest companies in the forest industry sector, Holmen and Södra, are to examine how self-driving vehicles can improve the work environment and enhance safety at sawmills and other industrial sites. This type of vehicle has great potential for transporting timber and sawn wood within the sites.Semcon’s autonomy specialists will join forces with the management of production development at Holmen and at Södra to carry out a feasibility study starting autumn 2021. This will include process mapping to identify which of the processes is best suited for

Saphnelo approved in Japan for systemic lupus erythematosus

28 September 2021 07:00 BST Saphnelo approved in Japan for systemic lupus erythematosus Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus AstraZeneca's Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment. The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on efficacy and safety

The planning of the world’s largest seasonal heat storage is well under way

YIT, Vantaa Energy and AFRY are planning the construction of the world’s largest seasonal heat storage using the alliance model. At one million cubic metres in size, the underground seasonal heat storage will have a total capacity that corresponds to the annual heating demand of a medium-sized Finnish city. The seasonal storage will play an important role in the phasing out of fossil fuels in energy production in the Vantaa region by 2026. It also supports the goal of carbon neutrality by 2030. The seasonal heat storage containing 140 °C water will be used to store renewable energy

K Group and Paulig join forces to promote sustainable coffee cultivation – 70,000 coffee plant seedlings to be planted in Nicaragua

K Group and Paulig are extending their collaboration to support the livelihood of coffee farmers and sustainable cultivation practices. The goal is to plant 70,000 new coffee plants at Paulig’s partner farms in Nicaragua. The customers of K grocery stores can take part in the project by buying Paulig’s Rainforest Alliance or UTZ-certified city coffee packages. Climate change and the extreme weather phenomena caused by it are among the biggest threats to the availability of coffee in the future. To ensure the best harvest and the continuity of coffee farms, farms should replace

InnCoCells – an EU-funded Horizon 2020 project developing safe and sustainable plant derived cosmetic ingredients with scientifically proven effects

Press release 28 September, 2021 InnCoCells – Innovative high-value cosmetic products from plants and plant cells – is a four-year collaborative research project that aims to revolutionize the way cosmetic ingredients are discovered, manufactured and developed into validated cosmetic products. For the next four years, 17 partners representing 11 countries in Europe will be working together to develop sustainable production systems for plant-derived cosmetic ingredients. The research is funded by the European Commission with a budget of €7.9 million and is coordinated by the VTT

Ericsson to support Malaysia’s digital transformation through nationwide 5G deployment

· Ericsson enters 10-year partnership with Digital Nasional Berhad (DNB) to deliver a nationwide 5G single wholesale network for Malaysia · 5G to accelerate Malaysia’s digital transformation and Industry 4.0 · Ericsson to provide end-to-end 5G, comprising core, radio access (RAN) and transport, operations and business support systems (OSS/BSS) and managed servicesMalaysia and its economy are poised to benefit from a 10-year 5G partnership between Ericsson (NASDAQ: ERIC) and Digital Nasional Berhad (DNB) to drive the nationwide deployment of the next-generation wireless cellular

Nel ASA: Receives purchase order from the Community of cities “Touraine Vallée de l’Indre (CCTVI)” for a hydrogen fueling station (H2Station™) to be located in the region of Tours in France

(Oslo, September 28, 2021) Nel Hydrogen Fueling, a subsidiary of Nel ASA (Nel, OSE:NEL) has received a purchase order from the Community of cities “Touraine Vallée de l’Indre" for one H2Station™ hydrogen fueling station to be used for light and heavy duty fuel cell electric vehicles in region of Tours, France. “We are delighted to announce that we have been chosen as supplier for a fueling station (H2Station™) for the Touraine Vallée de l’Indre in France. Nel Hydrogen is hereby passing an important landmark adding yet another country to its list of references.  We are looking forward to

Thailand’s 4-phase reopening plan from October until January

  The Tourism Authority of Thailand (TAT) would like to report that the Centre for COVID-19 Situation Administration (CCSA) has approved a four-phase timeline for the country’s reopening plan to revitalise the nationwide tourism industry. Pilot Phase (1-31 October, 2021) This will continue with the four popular beach resorts, which were the first destinations to reopen – beginning with Phuket on 1 July, then Surat Thani’s Samui, Ko Pha-ngan and Ko Tao on 15 July, and most recently Krabi and Phang-Nga on 16 August linking with Phuket under the 7+7 Extension arrangement.

Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market

Episurf Medical (Nasdaq: EPIS B) today announces that the company is investigating the opportunities for launching an implant system for the MTP joint of the foot in the US market. Episurf Medical has identified this market as a one with significant unmet medical needs. The company has begun the product development phase for this product, and targets the filing of a 510(k)-application to the US FDA for the Episealer® MTP system late 2022 or first half of 2023. Osteoarthritis (hallux rigidus) in the big toe (1[st] MTP joint) is a common medical condition, affecting around 2-2,5% of all

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

· Orismilast is a potential best-in-class PDE4 inhibitor in Phase 2 clinical development for the treatment of atopic dermatitis, psoriasis, and hidradenitis suppurativa · Innovent will be granted exclusive rights to research, develop and commercialize orismilast in China (including Mainland China, Hong Kong, Macau and Taiwan) · UNION will receive USD 20 million upfront and be entitled to receive additional milestone payments of up to USD 247 million as well as tiered royalties on sales of orismilast in China Hellerup, Denmark, San Francisco, U.S. and Suzhou, China, 28 September

Finnair moves forward with refinancing plan: sale and leaseback agreement for four A350 aircraft closed for cash proceeds in excess of 400 MUSD

Finnair Plc             Stock Exchange Release            28 September 2021 at 9.00 a.m. EEST  In conjunction with Finnair’s efforts to emerge from the corona crisis, the company is proceeding with its refinancing plan and has finalised a sale and leaseback arrangement for four of its Airbus A350 aircraft. In the arrangement, Finnair sold these aircraft – delivered between June 2017 and February 2019 – and has leased them back for its own operation. The operating lease period is, on average, 12 years and the counterparties are GE Capital Aviation Services (“GECAS”) and Pacific Investment

BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED

Lund, Sweden, 08:00 CET, 28-09-21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval in Q1 of 2022. In February of this year, the FDA requested further data and clarifications on BONESUPPORT’s DeNovo application. The

Peab renovates and expands elementary school in Helsinki

Peab has been commissioned to expand and renovate an elementary school in Pohjois Haaga in Helsinki. The customer is the city of Helsinki and the contract is worth EUR 14 million.The project entails a total renovation as well as construction of two new buildings. The current school building consists of three parts. “We have a lot of experience renovating school buildings in the capital region. We’re pleased that we can now carry out this project and continue to take advantage of the expertise in our organization,” says Marko Rinkinen, Region Manager Peab. The project is a turnkey

Patent in India enables a large future market for myFC's technology

One of myFC’s patents has been approved by the Indian Patent Office. The patent protects a smooth and gentle method for efficiently starting up the fuel cells and transitioning to a power-generating phase, while maintaining the long life of the fuel cells.India, with a population of almost 1.4 billion, is a country that invests heavily in hydrogen technology, focusing on using energy resources more efficiently without losing competitiveness, and on improving environmental conditions, especially in highly populated urban environments.Green hydrogen technology has great advantages in terms of

Sedana Medical receives approval in Germany

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany.The approval applies to the drug Sedaconda (isoflurane) for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in Germany. The application has been approved by the German pharmaceutical authority BfArM and is based on the DCP approval Sedana Medical received in July. Since the European DCP approval in July 2021, Sedaconda (isoflurane) has now received national approvals in

Changes in Teknos Group Management – Edward Skärström, CIO, leaves the company

Edward Skärström, CIO, has decided to leave Teknos Group. The recruitment process of successor will be started immediately. Edward will continue in his current role as CIO, Teknos Management Team member, until the new CIO is recruited.Edward Skärström, CIO, has decided to leave Teknos Group. Edward joined Teknos in 2015. In 2017 he was appointed Chief Information Officer (CIO) for Teknos Group and the Group ICT organization was formed. Since 2019 Edward has been a member of Teknos Management Team (TMT). “Eddi’s structured manner, calm way of addressing topics and ability to spar and

Expo 2020: LKAB and Sweden show the way towards a sustainable future

On October 1st Expo 2020 opens in Dubai, where the Swedish Government together with the industry will present new technology and innovations on a global arena. As one of several official partners, LKAB is showcasing the most recent advances in the iron and steel industry that pave the way for a necessary global transition.- There is tremendous global interest in what is happening in our part of the world right now. We are breaking new ground on the journey towards fossil-free iron and steelmaking, which is the greatest thing we can do together for the climate. Expo is a unique opportunity

Polygon completes early redemption of all 2018/2023 notes

THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, WITHIN OR TO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.As previously announced, Polygon AB (publ) (the “Company” or “Polygon”) has resolved on a voluntary redemption in full of all outstanding senior secured fixed rate notes with ISIN SE0010830950 (

Microscopic metavehicles powered by nothing but light

  Click here to watch a video of the metavehicles in action Researchers from Chalmers University of Technology, Sweden, have succeeded in creating tiny vehicles powered by nothing but light. By layering an optical metasurface onto a microscopic particle, and then using a light source to control it, they succeeded in moving the tiny vehicles in a variety of complex and precise ways – and even using them to transport other objects.  Light has an inherent power to move microscopic objects – a property previously used to

Invitation to Kungsleden’s presentation of interim report for January–September 2021

On Tuesday, 19 October, Kungsleden will publish its interim report for January–September 2021. At 10:00 a.m. (CEST), Kungsleden invites investors, financial analysts and the press to a live presentation of our interim report where CEO Biljana Pehrsson and Deputy CEO and CFO Ylva Sarby Westman will comment on the company’s performance.The report will be published at 6:55 a.m. (CEST) and will be available here . As of 9:00 a.m. (CEST) the slides from the presentation will be available from here 

Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

Stockholm, September 28, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD). The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early Alzheimer’s disease and

There are no items matching the current filter
There are no more items matching the current filter
Back to top